Methylene blue: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Protected "Methylene blue": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite))) |
||
| (12 intermediate revisions by one other user not shown) | |||
| Line 2: | Line 2: | ||
|authorTag={{TA}} | |authorTag={{TA}} | ||
|genericName=Methylene blue | |genericName=Methylene blue | ||
|aOrAn=a | |||
|drugClass=heterocyclic aromatic chemical compound | |||
|indicationType=treatment | |indicationType=treatment | ||
|indication= | |indication=drug induced methemoglobinemia | ||
|adverseReactions=Hypertension, hypotension, sweating symptom, abdominal pain, diarrhea, nausea, vomiting, dizziness, headache and confusion | |adverseReactions=[[Hypertension]], [[hypotension]], sweating symptom, [[abdominal pain]], [[diarrhea]], [[nausea]], [[vomiting]], [[dizziness]], [[headache]] and [[confusion]] | ||
|blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b> | |blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b> | ||
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content) | |blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content) | ||
| Line 17: | Line 19: | ||
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Methylene blue in pediatric patients. | |offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Methylene blue in pediatric patients. | ||
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Methylene blue in pediatric patients. | |offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Methylene blue in pediatric patients. | ||
|contraindications=*Methylene blue can cause fetal harm when administered to a pregnant woman. An association exists between the use of methylene blue in amniocentesis and atresia of the ileum and jejunum, ileal occlusions and other adverse effects in the neonate. Methylene blue is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. | |contraindications=*Methylene blue can cause fetal harm when administered to a pregnant woman. An association exists between the use of methylene blue in [[amniocentesis]] and [[atresia]] of the ileum and jejunum, ileal occlusions and other adverse effects in the neonate. Methylene blue is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. | ||
*Intraspinal injection is contraindicated. | *Intraspinal injection is contraindicated. | ||
*Methylene blue is contraindicated in patients with a known hypersensitivity to the drug. | *Methylene blue is contraindicated in patients with a known [[hypersensitivity]] to the drug. | ||
|warnings=*Methylene Blue should not be given by subcutaneous or intrathecal injection. | |warnings=*Methylene Blue should not be given by subcutaneous or intrathecal injection. | ||
*Methylene blue is a potent monoamine oxidase inhibitor: Methylene blue has been demonstrated to be a potent monoamine oxidase inhibitor (MAOI) and may cause potentially fatal serotonin toxicity (serotonin syndrome) when combined with serotonin reputake inhibitors (SRIs). | *Methylene blue is a potent [[monoamine oxidase inhibitor]]: Methylene blue has been demonstrated to be a potent monoamine oxidase inhibitor (MAOI) and may cause potentially fatal serotonin toxicity ([[serotonin syndrome]]) when combined with serotonin reputake inhibitors (SRIs). Serotonin toxicity is characterized by development of neuromuscular hyperactivity ([[tremor]], [[clonus]], [[myoclonus]] and [[hyperreflexia]], and, in the advanced stage, pyramidal rigidity); autonomic hyperactivity (diaphoresis, fever, [[tachycardia]], [[tachypnoea]], and [[mydraisis]]); and altered mental status ([[agitation]], excitement, and in the advanced stage, [[confusion]]). If methylene blue is judged to be indicated, SRIs must be ceased, prior to treatment/procedure/surgery. | ||
===Precautions=== | ===Precautions=== | ||
*Glucose-6-Phosphate Dehydrogenase Deficiency (G6PD): Methylene blue should be avoided in patients with G6PD deficiency due to the risk of paradoxical methemoglobinemia and hemolysis. | *[[Glucose-6-Phosphate Dehydrogenase Deficiency]] ([[G6PD]]): Methylene blue should be avoided in patients with G6PD deficiency due to the risk of paradoxical [[methemoglobinemia]] and [[hemolysis]]. | ||
|clinicalTrials=*Large intravenous doses of Methylene Blue produce nausea, abdominal and precordial pain, dizziness, headache, profuse sweating, [[confusion|mental confusion]] and the formation of methemoglobin. | |clinicalTrials=*Large intravenous doses of Methylene Blue produce [[nausea]], abdominal and [[precordial pain]], [[dizziness]], [[headache]], profuse sweating, [[confusion|mental confusion]] and the formation of methemoglobin. | ||
|postmarketing=*There is limited information regarding <i>postmarketing experience</i> | |postmarketing=*There is limited information regarding <i>postmarketing experience</i> | ||
|drugInteractions=*Methylene blue may interact with any drug that acts as a serotonin reuptake inhibitor (SRI) including, amongst others, selective serotonin reuptake inhbitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), norepinephrine-dopamine reuptake inhibitors (NDRIs), triptans and ergot alkaloids; such combinations may have the consequence of potentially fatal serotonin toxicity (serotonin syndrome). Methylene blue should not be co-administered with any drug that acts as an SRI. | |drugInteractions=*Methylene blue may interact with any drug that acts as a serotonin reuptake inhibitor (SRI) including, amongst others, selective serotonin reuptake inhbitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), [[tricyclic antidepressants]] (TCAs), norepinephrine-dopamine reuptake inhibitors (NDRIs), [[triptans]] and ergot alkaloids; such combinations may have the consequence of potentially fatal serotonin toxicity ([[serotonin syndrome]]). Methylene blue should not be co-administered with any drug that acts as an SRI. | ||
|FDAPregCat=X | |FDAPregCat=X | ||
|useInPregnancyFDA=*Epidemiologic evidence exists that Methylene blue is a teratogen. An association exists between the use of methylene blue in amniocentesis and atresia of the ileum and jejunum, ileal occlusions and other adverse effects in the neonate. Methylene blue Injection should not be administered to pregnant women during amniocentesis due to the risk of teratogenicity and other newborn adverse effects | |useInPregnancyFDA=*Epidemiologic evidence exists that Methylene blue is a teratogen. An association exists between the use of methylene blue in [[amniocentesis]] and atresia of the ileum and jejunum, ileal occlusions and other adverse effects in the neonate. Methylene blue Injection should not be administered to pregnant women during [[amniocentesis]] due to the risk of teratogenicity and other newborn adverse effects | ||
|useInRenalImpair=*Renal Failure: Methylene blue should be used with caution in patients with severe renal impairment . | |useInRenalImpair=*Renal Failure: Methylene blue should be used with caution in patients with severe renal impairment . | ||
|administration=*Intravenous. | |administration=*Intravenous. | ||
|monitoring=*There is limited information regarding <i>drug monitoring</i>. | |monitoring=*There is limited information regarding <i>drug monitoring</i>. | ||
|IVCompat=*There is limited information regarding <i>IV compatibility</i>. | |IVCompat=*There is limited information regarding <i>IV compatibility</i>. | ||
|drugBox={{ | |drugBox={{chembox2 | ||
| Watchedfields = changed | | Watchedfields = changed | ||
| verifiedrevid = 476992187 | | verifiedrevid = 476992187 | ||
| Line 68: | Line 70: | ||
| ATCCode_suffix = AB17 | | ATCCode_suffix = AB17 | ||
| ATC_Supplemental = {{ATC|V04|CG05}} | | ATC_Supplemental = {{ATC|V04|CG05}} | ||
}} | |||
|Section2={{Chembox Properties | |||
| Formula = C<sub>16</sub>H<sub>18</sub>N<sub>3</sub>SCl | |||
| MolarMass = 319.85 g/mol | |||
| Density = | |||
| MeltingPtC = 100 to 110 | |||
| Melting_notes = (with decomposition) | |||
| BoilingPt = Decomposes | |||
}} | |||
}} | }} | ||
|mechAction=*Methylene blue is Phenothiazin-5-ium, 3,7-bis (dimethylamino)-, chloride, trihydrate. It will produce two opposite actions on hemoglobin. Low concentrations will convert methemoglobin to hemoglobin. High concentrations convert the ferrous iron of reduced hemoglobin to ferric iron which results in the formation of methemoglobin. | |mechAction=*Methylene blue is Phenothiazin-5-ium, 3,7-bis (dimethylamino)-, chloride, trihydrate. It will produce two opposite actions on hemoglobin. Low concentrations will convert methemoglobin to hemoglobin. High concentrations convert the ferrous iron of reduced hemoglobin to ferric iron which results in the formation of methemoglobin. | ||
| Line 96: | Line 107: | ||
|lookAlike=*There is limited information regarding <i>Look-Alike Drug Names</i>. | |lookAlike=*There is limited information regarding <i>Look-Alike Drug Names</i>. | ||
}} | }} | ||
[[Category:Antidotes]] | |||
[[Category:Histology]] | |||
[[Category:Drug]] | |||
[[Category:Vital stains]] | |||
[[Category:Monoamine oxidase inhibitors]] | |||
[[Category:Phenothiazines]] | |||
[[Category:Chlorides]] | |||
Latest revision as of 16:42, 20 August 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Turky Alkathery, M.D. [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Methylene blue is a heterocyclic aromatic chemical compound that is FDA approved for the treatment of drug induced methemoglobinemia. Common adverse reactions include Hypertension, hypotension, sweating symptom, abdominal pain, diarrhea, nausea, vomiting, dizziness, headache and confusion.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Indications
- Drug induced methemoglobinemia
Dosage
- 0.1 to 0.2 mL per kilogram of body weight (0.045 to 0.09 mL per pound of body weight). Inject Methylene Blue intravenously very slowly over a period of several minutes.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
- There is limited information regarding Off-Label Guideline-Supported Use of Methylene blue in adult patients.
Non–Guideline-Supported Use
- There is limited information regarding Off-Label Non–Guideline-Supported Use of Methylene blue in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Safety and effectiveness in pediatric patients have not been established.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Methylene blue in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Methylene blue in pediatric patients.
Contraindications
- Methylene blue can cause fetal harm when administered to a pregnant woman. An association exists between the use of methylene blue in amniocentesis and atresia of the ileum and jejunum, ileal occlusions and other adverse effects in the neonate. Methylene blue is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
- Intraspinal injection is contraindicated.
- Methylene blue is contraindicated in patients with a known hypersensitivity to the drug.
Warnings
- Methylene Blue should not be given by subcutaneous or intrathecal injection.
- Methylene blue is a potent monoamine oxidase inhibitor: Methylene blue has been demonstrated to be a potent monoamine oxidase inhibitor (MAOI) and may cause potentially fatal serotonin toxicity (serotonin syndrome) when combined with serotonin reputake inhibitors (SRIs). Serotonin toxicity is characterized by development of neuromuscular hyperactivity (tremor, clonus, myoclonus and hyperreflexia, and, in the advanced stage, pyramidal rigidity); autonomic hyperactivity (diaphoresis, fever, tachycardia, tachypnoea, and mydraisis); and altered mental status (agitation, excitement, and in the advanced stage, confusion). If methylene blue is judged to be indicated, SRIs must be ceased, prior to treatment/procedure/surgery.
Precautions
- Glucose-6-Phosphate Dehydrogenase Deficiency (G6PD): Methylene blue should be avoided in patients with G6PD deficiency due to the risk of paradoxical methemoglobinemia and hemolysis.
Adverse Reactions
Clinical Trials Experience
- Large intravenous doses of Methylene Blue produce nausea, abdominal and precordial pain, dizziness, headache, profuse sweating, mental confusion and the formation of methemoglobin.
Postmarketing Experience
- There is limited information regarding postmarketing experience
Drug Interactions
- Methylene blue may interact with any drug that acts as a serotonin reuptake inhibitor (SRI) including, amongst others, selective serotonin reuptake inhbitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), norepinephrine-dopamine reuptake inhibitors (NDRIs), triptans and ergot alkaloids; such combinations may have the consequence of potentially fatal serotonin toxicity (serotonin syndrome). Methylene blue should not be co-administered with any drug that acts as an SRI.
Use in Specific Populations
Pregnancy
- Epidemiologic evidence exists that Methylene blue is a teratogen. An association exists between the use of methylene blue in amniocentesis and atresia of the ileum and jejunum, ileal occlusions and other adverse effects in the neonate. Methylene blue Injection should not be administered to pregnant women during amniocentesis due to the risk of teratogenicity and other newborn adverse effects
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Methylene blue in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Methylene blue during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Methylene blue in women who are nursing.
Pediatric Use
There is no FDA guidance on the use of Methylene blue in pediatric settings.
Geriatic Use
There is no FDA guidance on the use of Methylene blue in geriatric settings.
Gender
There is no FDA guidance on the use of Methylene blue with respect to specific gender populations.
Race
There is no FDA guidance on the use of Methylene blue with respect to specific racial populations.
Renal Impairment
- Renal Failure: Methylene blue should be used with caution in patients with severe renal impairment .
Hepatic Impairment
There is no FDA guidance on the use of Methylene blue in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Methylene blue in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Methylene blue in patients who are immunocompromised.
Administration and Monitoring
Administration
- Intravenous.
Monitoring
- There is limited information regarding drug monitoring.
IV Compatibility
- There is limited information regarding IV compatibility.
Overdosage
There is limited information regarding Methylene blue overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
Template:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox E numberTemplate:Chembox MeltingPtTemplate:Chembox BoilingPtTemplate:Chembox Supplement| Template:Chembox header2 | Methylene blue | |
|---|---|
| Identifiers | |
3D model (JSmol)
|
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C16H18N3SCl | |
| Molar mass | 319.85 g/mol |
| Template:Chembox header2 | Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox disclaimer and references | |
Mechanism of Action
- Methylene blue is Phenothiazin-5-ium, 3,7-bis (dimethylamino)-, chloride, trihydrate. It will produce two opposite actions on hemoglobin. Low concentrations will convert methemoglobin to hemoglobin. High concentrations convert the ferrous iron of reduced hemoglobin to ferric iron which results in the formation of methemoglobin.
Structure
- Methylene Blue Injection, USP is a sterile solution of methylene blue in water for injection suitable for parenteral administration.
- Each mL of solution contains 10 mg of methylene blue and water for injection q.s. pH adjusted with hydrochloric acid and/or sodium hydroxide when necessary.
Pharmacodynamics
- There is limited information regarding pharmacodynamics.
Pharmacokinetics
- There is limited information regarding pharmacokinetics.
Nonclinical Toxicology
- There is limited information regarding nonclinical toxicology.
Clinical Studies
- There is limited information regarding clinical studies.
How Supplied
Methylene Blue Injection, USP, 1% is supplied as follows:
NDC 17478-504-01 1 mL in 2 cc (partially filled) vials in packages of 10.
NDC 17478-504-10 10 mL vials in packages of 10.
The vials are packaged with a Flip Tear-Off Seal. The seal can either be flipped normally to reveal the rubber stopper or be totally removed so the rubber stopper can be taken out of the vial. The plastic button is attached to the metal seal, which when pulled, tears the seal at the score line allowing the metal portion to be removed.
Storage
STORAGE: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
Images
Drug Images
{{#ask: Page Name::Methylene blue |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Methylene blue |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
- There is limited information regarding Patient Counseling Information.
Precautions with Alcohol
Alcohol-Methylene blue interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
- METHYLENE BLUE®[1]
Look-Alike Drug Names
- There is limited information regarding Look-Alike Drug Names.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.